Related references
Note: Only part of the references are listed.Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region?
R. Banerjee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Guilherme P. Ramos et al.
INFLAMMATORY BOWEL DISEASES (2018)
Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis
Siddharth Singh et al.
PLOS ONE (2018)
Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
Siew C. Ng et al.
INFLAMMATORY BOWEL DISEASES (2018)
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Stanley Cohen et al.
RHEUMATOLOGY AND THERAPY (2018)
Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study
Aye Aye Thi et al.
FRONTLINE GASTROENTEROLOGY (2018)
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Dong Il Park et al.
INTESTINAL RESEARCH (2018)
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Dong Il Park et al.
INTESTINAL RESEARCH (2018)
Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea
S. N. Hong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease
Jae Hee Cheon
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Infliximab-induced tuberculosis in patients with UC: Experience from India-a country with high prevalence of tuberculosis
Amarender S. Puri et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
Fabrizio Cantini et al.
MEDIATORS OF INFLAMMATION (2017)
Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients
Bee Eng Tan et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Insights on the use of biosimilars in the treatment of inflammatory bowel disease
Michael K. Zheng et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease
W. A. Bye et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease
Shu-Chen Wei et al.
INTESTINAL RESEARCH (2017)
Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease
Shu-Chen Wei et al.
INTESTINAL RESEARCH (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Aurelien Amiot et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
Stefanos Bonovas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015
Charles N. Bernstein et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2016)
Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment
D. Carpio et al.
JOURNAL OF CROHNS & COLITIS (2016)
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort
Yael Abitbol et al.
JOURNAL OF CROHNS & COLITIS (2016)
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Rein M. G. J. Houben et al.
PLOS MEDICINE (2016)
Advances in the development of new biologics in inflammatory bowel disease
Bella Ungar et al.
ANNALS OF GASTROENTEROLOGY (2016)
The pros and cons of the QuantiFERON test for the diagnosis of tuberculosis, prediction of disease progression, and treatment monitoring
Elvis Ndukong Ndzi et al.
INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY (2016)
Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease
P. Luthra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Infection risk associated with anti-TNF-α agents: a review
Giuseppe Murdaca et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden
Seung Min Jung et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2015)
The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
Ja Min Byun et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2015)
Epidemiology and risk factors for IBD
Ashwin N. Ananthakrishnan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor
Ja Min Byun et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Seminar Report From the 2014 Taiwan Society of Inflammatory Bowel Disease (TSIBD) Spring Forum (May 24th, 2014): Crohn's Disease Versus Intestinal Tuberculosis Infection
Meng-Tzu Weng et al.
INTESTINAL RESEARCH (2015)
Estimated Rate of Reactivation of Latent Tuberculosis Infection in the United States, Overall and by Population Subgroup
Kimberly M. Shea et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2014)
Tumor necrosis factor inhibitors - state of knowledge
Krzysztof Lis et al.
ARCHIVES OF MEDICAL SCIENCE (2014)
Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection
Madhukar Pai et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2014)
Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
Fabrizio Cantini et al.
JOURNAL OF RHEUMATOLOGY (2014)
Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches
Delia Goletti et al.
JOURNAL OF RHEUMATOLOGY (2014)
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Top-Down or Step-Up Treatment in Crohn's Disease?
Gerhard Rogler
DIGESTIVE DISEASES (2013)
Current incidence of active tuberculosis in IBD patients treated with anti-TNF agents: Still room for improvement
Míriam Mañosa et al.
Journal of Crohns & Colitis (2013)
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening
Aranzazu Jauregui-Amezaga et al.
JOURNAL OF CROHNS & COLITIS (2013)
Treatment of inflammatory bowel disease (IBD)
Anand B. Pithadia et al.
PHARMACOLOGICAL REPORTS (2011)
Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up (Reprinted from Gastroenterology Clinics of North America, vol 38)
Shane M. Devlin et al.
MEDICAL CLINICS OF NORTH AMERICA (2010)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement
U. Mack et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans
Heiko Bruns et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy
Der-Yuan Chen et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Tumor Necrosis Factor Blockers Influence Macrophage Responses to Mycobacterium tuberculosis
James Harris et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent
Deepak N. Amarapurkar et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
T. Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Risk for active tuberculosis in inflammatory bowel disease patients
Faten N. Aberra et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment
LP Ormerod et al.
THORAX (2005)
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
